CO6541606A2 - Espiroindolinona- pirrolidinas - Google Patents

Espiroindolinona- pirrolidinas

Info

Publication number
CO6541606A2
CO6541606A2 CO12086101A CO12086101A CO6541606A2 CO 6541606 A2 CO6541606 A2 CO 6541606A2 CO 12086101 A CO12086101 A CO 12086101A CO 12086101 A CO12086101 A CO 12086101A CO 6541606 A2 CO6541606 A2 CO 6541606A2
Authority
CO
Colombia
Prior art keywords
pirrolidinas
espiroindolinona
compounds
nicancerous
esters
Prior art date
Application number
CO12086101A
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Zhuming Zhang
Jing Zhang
Nan Jiang
Bradford James Graves
Qingjie Ding
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6541606A2 publication Critical patent/CO6541606A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan compuestos de la fórmula (I)en la que X, Y y de R1 a R8 tienen los significados aquí definidos, junto con, los enantiómeros, las sales y los esteres farmacéuticamente aceptables de los mismos. Estos compuestos son útiles como agentes nticancerosos.
CO12086101A 2009-12-02 2012-05-24 Espiroindolinona- pirrolidinas CO6541606A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26579209P 2009-12-02 2009-12-02
US38805410P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
CO6541606A2 true CO6541606A2 (es) 2012-10-16

Family

ID=43608656

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12086101A CO6541606A2 (es) 2009-12-02 2012-05-24 Espiroindolinona- pirrolidinas

Country Status (26)

Country Link
US (1) US8088815B2 (es)
EP (1) EP2507243B1 (es)
JP (1) JP5647262B2 (es)
KR (1) KR101418191B1 (es)
CN (1) CN102741257B (es)
AR (1) AR079226A1 (es)
AU (1) AU2010326855B2 (es)
BR (1) BR112012012872A2 (es)
CA (1) CA2781823A1 (es)
CL (1) CL2012001405A1 (es)
CO (1) CO6541606A2 (es)
CR (1) CR20120259A (es)
EC (1) ECSP12011945A (es)
ES (1) ES2543468T3 (es)
HK (1) HK1173720A1 (es)
IL (1) IL220010A (es)
MA (1) MA33976B1 (es)
MX (1) MX2012006260A (es)
MY (1) MY160596A (es)
NZ (1) NZ600024A (es)
PE (1) PE20121334A1 (es)
RU (1) RU2571100C2 (es)
SG (1) SG181465A1 (es)
TW (1) TW201129571A (es)
WO (1) WO2011067185A1 (es)
ZA (1) ZA201204036B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095063A1 (en) * 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
BR112012011317A2 (pt) 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
WO2012121361A1 (ja) * 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
ES2712973T3 (es) 2014-04-17 2019-05-17 Univ Michigan Regents Inhibidores de MDM2 y métodos terapéuticos que usan los mismos
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
ES2959097T3 (es) * 2014-08-18 2024-02-20 Hudson Biopharma Inc Espiropirrolidinas como inhibidores de MDM2
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
RU2629750C2 (ru) * 2015-04-09 2017-09-01 Ян Андреевич Иваненков НОВЫЕ ДИСПИРО-ИНДОЛИНОНЫ, ИНГИБИТОРЫ MDM2/p53 ВЗАИМОДЕЙСТВИЯ, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
EA036013B1 (ru) 2015-10-09 2020-09-14 Бёрингер Ингельхайм Интернациональ Гмбх Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
CN113788818A (zh) * 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
CN105949221B (zh) * 2016-05-11 2017-08-25 湖南科技大学 一种含螺吲哚‑2‑酮衍生物及其制备方法和作为抗癌药物的应用
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
RU2730287C1 (ru) * 2019-08-30 2020-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Новые 2',5'-диарилспиро[индол-3,3'-пирролидин]-2(1н)-оны и способ их получения
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
EP4204812A2 (en) 2020-08-27 2023-07-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
WO2022159644A1 (en) * 2021-01-23 2022-07-28 Newave Pharmaceutical Inc. Spirocyclic mdm2 modulator and uses thereof
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN115215872A (zh) * 2021-04-15 2022-10-21 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
CN113387957B (zh) * 2021-06-09 2022-08-09 江苏亚尧生物科技有限公司 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11919910B2 (en) * 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN114773327B (zh) * 2022-04-18 2023-08-18 广东优康精细化工有限公司 一种吡噻菌胺中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759935A (en) 1953-02-18 1956-08-21 Bristol Lab Inc Substituted 3-phenyloxindoles
US3441570A (en) 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3686210A (en) 1970-01-13 1972-08-22 American Home Prod 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds
US4020179A (en) 1975-05-15 1977-04-26 Richardson-Merrell Inc. 7-Substituted-2-indolinones
JPS55129284A (en) 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
DE3714473A1 (de) 1987-04-30 1988-11-10 Basf Ag Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose
RU2084449C1 (ru) * 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
AU7450898A (en) 1997-05-28 1998-12-30 Tokyo Tanabe Company Limited Indole compounds
US6511974B1 (en) 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
JP2000191661A (ja) 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
EP1426375A3 (en) 1999-07-21 2004-12-15 AstraZeneca AB Analgesic spiroindole derivatives
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1487792A1 (en) 2002-03-15 2004-12-22 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
DE202004014849U1 (de) * 2004-09-23 2005-02-03 Trw Automotive Safety Systems Gmbh Vorrichtung zur Bestimmung eines absoluten Drehwinkels
JP5125501B2 (ja) 2005-01-28 2013-01-23 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物
EA019566B1 (ru) 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
ATE495176T1 (de) 2006-03-13 2011-01-15 Hoffmann La Roche Spiroindolinon-derivate
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
US7737174B2 (en) * 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
SG174107A1 (en) 2006-08-30 2011-09-29 Univ Michigan New small molecule inhibitors of mdm2 and the uses thereof
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008080822A1 (en) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Epimerization methodologies for recovering stereo isomers in high yield and purity
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
DK2340021T3 (da) * 2008-09-18 2012-12-10 Hoffmann La Roche Substituerede pyrrolidin-2-carboxamider
BR112012011317A2 (pt) * 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
SG184288A1 (en) * 2010-04-09 2012-11-29 Univ Michigan Biomarkers for mdm2 inhibitors for use in treating disease

Also Published As

Publication number Publication date
HK1173720A1 (en) 2013-05-24
SG181465A1 (en) 2012-07-30
AU2010326855A1 (en) 2012-06-21
IL220010A0 (en) 2012-07-31
MA33976B1 (fr) 2013-02-01
CL2012001405A1 (es) 2012-09-28
CN102741257A (zh) 2012-10-17
JP5647262B2 (ja) 2014-12-24
PE20121334A1 (es) 2012-10-12
WO2011067185A1 (en) 2011-06-09
JP2013512869A (ja) 2013-04-18
US8088815B2 (en) 2012-01-03
RU2571100C2 (ru) 2015-12-20
RU2012125763A (ru) 2014-01-10
BR112012012872A2 (pt) 2017-10-10
NZ600024A (en) 2014-08-29
KR20120101481A (ko) 2012-09-13
TW201129571A (en) 2011-09-01
IL220010A (en) 2014-03-31
EP2507243B1 (en) 2015-06-10
KR101418191B1 (ko) 2014-07-09
US20110130398A1 (en) 2011-06-02
CR20120259A (es) 2012-07-12
ES2543468T3 (es) 2015-08-19
MX2012006260A (es) 2012-06-19
CN102741257B (zh) 2015-03-04
EP2507243A1 (en) 2012-10-10
CA2781823A1 (en) 2011-06-09
ZA201204036B (en) 2013-02-27
AR079226A1 (es) 2012-01-04
ECSP12011945A (es) 2012-07-31
MY160596A (en) 2017-03-15
AU2010326855B2 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
CO6541606A2 (es) Espiroindolinona- pirrolidinas
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP13013074A (es) Nuevos derivados de piridina
CO6361910A2 (es) Pirrolidina-2-carboxamidas sustituidas
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CR20150250A (es) Nuevos derivados de piridina
CR20120594A (es) Compuestos heteroarilo nitrogenados
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150204A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY34365A (es) Compuestos heterociclicos
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
PA8779101A1 (es) "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales"
CR20110219A (es) Ácidos naftilacéticos
CU24078B1 (es) Tres compuestos de sulfonamidas anilladas
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
UY33176A (es) Derivados de oxazolopirimidina sustituida en 2, 5, 7.
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico

Legal Events

Date Code Title Description
FA Application withdrawn